Pregled bibliografske jedinice broj: 1281505
Symptom severity in schizophrenia patients with NPAS3, dysbindin-1 and/or TRIOBP protein pathology in their blood serum: a PANSS-based follow up study
Symptom severity in schizophrenia patients with NPAS3, dysbindin-1 and/or TRIOBP protein pathology in their blood serum: a PANSS-based follow up study // Psychiatria Danubina, 35 (2023), 2; 180-186 doi:10.24869/psyd.2023.180 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1281505 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Symptom severity in schizophrenia patients with
NPAS3, dysbindin-1 and/or TRIOBP protein pathology
in their blood serum: a PANSS-based follow up
study
Autori
Aristea Pavešić Radonja ; Sandra Blazević Zelić ; Gordana Rubeša ; Nicholas J. Bradshaw
Izvornik
Psychiatria Danubina (0353-5053) 35
(2023), 2;
180-186
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Blood serum ; PANSS ; Protein aggregation ; Proteinopathy ; Schizophrenia
Sažetak
Background: It has been proposed that aggregation of specific proteins in the brain may be a pathological element in schizophrenia and other chronic disorders. Multiple such aggregating proteins have now been implicated through post mortem investigation, including NPAS3 (Neuronal PAS domain protein 3), dysbindin 1 (encoded by the DTNBP1, Dystrobrevin Binding Protein 1, gene) and TRIOBP (Trio-Binding Protein, multiple isoforms). While the presence of protein aggregates in the brain is interesting in terms of understanding pathology, it is impractical as a biomarker. These proteins were therefore investigated recently in blood serum of schizophrenia patients and controls, showing patients to have higher levels of NPAS3 in their serum generally. TRIOBP-1 and dysbindin-1 were also found in an insoluble state, implying aggregation, but did not clearly corresponding to disease state. Subject and methods: We revisit 47 of the originally recruited 50 patients with schizophrenia, all of whom are Croatian and aged between 18 and 72. We assessed their symptom specificity and severity using PANSS (the Positive and Negative Symptoms Scale), comparing those with NPAS3, insoluble dysbindin-1 and/or insoluble TRIOBP-1 in their blood serum to those lacking any such protein dysregulation. Results: The frequency of each individual potential protein pathology among these patients was too low for meaningful statistical analysis, however the 11 patients that displayed one or more of these pathologies (NPAS3, dysbindin-1, TRIOBP-1 and/or TRIOBP-5/6) showed a subtle but significant increase in total PANSS scores compared to the 36 patients displaying none of the pathologies (p = 0.031), seemingly driven principally by increased scores on the general psychopathology scale. Conclusion: While the numbers of patients involved do not allow firm conclusions to be drawn at this time, this provides the first indication that disturbed proteostasis in blood serum, of proteins that aggregate in the brains of schizophrenia patients, may correlate with the severity of schizophrenia symptoms.
Izvorni jezik
Engleski
Znanstvena područja
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)
POVEZANOST RADA
Projekti:
--IP-2018-01-9424 - Istraživanje shizofrenije kroz ekspresiju netopivih proteina (CandidIskren) (Bradshaw, Nicholas James) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka,
Sveučilište u Rijeci - Odjel za biotehnologiju
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Scopus
- MEDLINE